- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03072667
Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall purpose of the treatment is to offer alternative treatment to children who developed parenteral nutrition-associated liver disease (PNALD) and have not responded positively to currently available medical therapies. PNALD develops in newborns dependent on parenteral nutrition (PN) and are unable to tolerate adequate enteral feedings to support fluid and nutritional fluids; although PN is necessary and life sustaining, it can result in severe liver disease.
The investigators want to see if a form of intravenous fat mixture, Omegaven, helps in the treatment of children with PNALD. Experimental data has shown that the intravenous fat mixture (Intralipid) that is currently being used as a part of newborn PN, may be contributing to the liver disease. Omegaven is different fat mixture manufactured and used in Europe in adults. It is different in that it is made from highly refined fish oil, while Intralipid is made from soybeans. Case control studies only, and not randomized clinical trials, show that Omegaven may reverse or treat PNALD. Since Omegaven is not currently approved for use in the United States, treatment IND was obtained from Food and Drug Administration (FDA).
Feeding intolerance is a common pathway of a broad array of medical and surgical disease states encountered in the neonatal population. Consequently, a high percentage of patients in neonatal intensive care units (NICU) need to rely on PN if they are to survive and grow. Through decades of research the development of PN has been a great success in that its use has maintained countless patients in sufficient nutritional status to recover from medical or surgical conditions. However, one complication of PN that remains poorly understood and that still causes considerable morbidity and mortality is PNALD.
There are a wide variety of case scenarios for PNALD. There are scenarios in which newborns suffer irrecoverable bowel loss from some process (e.g., necrotizing enterocolitis totalis, mid gut volvulus) and consequently require long term PN as they await bowel transplant; as a result they almost always also require liver transplant secondary to PNALD. This further delays their surgery as they wait for two organs instead of one (Chungfat, Dixler et al. 2007). More commonly, cases involve patients who have prolonged bowel dysfunction that requires long term use of PN but who slowly recover and gradually transition to enteral feeds. For these infants the race between bowel recovery and PNALD progression often decides whether the patient lives or dies.
- Although the etiology of PNALD is poorly understood and likely to be multi-factorial (Steinbach, Clark et al. 2008), recent animal research and human case studies suggest that altering the dose and the composition of the lipid component of PN might alter the course of PNALD (Alwayn, Gura et al. 2005; Gura, Parsons et al. 2005; Gura, Duggan et al. 2006; Gura, Lee et al. 2008). The lipid products used for PN in the United States are derived from soy oil; the brand used at Cardinal Glennon Children's Hospital is Intralipid®. Soy-based PN lipids are rich in omega-6 FA and also contain small amounts of omega-3 FA in the form of linolenic acid precursor. The potential toxicity of omega-6 fatty acids as it relates to PNALD has been recently revealed (Diamond, Sterescu et al. 2008; de Meijer, Gura et al 2009). This FA composition is sufficient to prevent essential FA deficiency (EFAD), historically measured as the ratio of specific omega-6 FA in the blood (Gura, Lee et al 2009).
In a published article (Gura, Duggan et al. 2006) reporting 2 cases in depth and in a subsequent paper (Gura, Lee et al. 2008) reporting 18 patients with established PNALD who required continued PN, investigators replaced the standard soy based lipid component of PN with a fish oil derived parenteral lipid (Omegaven™) that contains a high percentage (30 to 60%) of omega-3 FA. This therapy, which is still experimental in the United States, was associated with a gradual but ultimately profound correction of PNALD as indicated by laboratory markers such as conjugated bilirubin and circulating liver enzymes; the median time to reduce serum direct bilirubin from >2mg/dl to <2mg/dl was 9.4 weeks. No significant adverse effects of Omegaven™ in the doses utilized were identified.
The current study is to identify infants with PNALD of moderate severity or worse, defined as two consecutive measurements of direct bilirubin of 3 mg/dL after being on PN for > 3 weeks and who are anticipated to require PN for another 3 weeks, which puts them at risk of further progression of PNALD. For inclusion, other causes of liver disease must be ruled out. Upon meeting entry criteria, infant families will be offered, through an Institutional Review Board (IRB) approved consent process, the same treatment protocol for their infants that was successfully applied in the above cited clinical cases and detailed below. Monitoring for side effects, complications and disease progression or regression will be instituted. Therapy will be stopped when direct bilirubin is < 1 mg/dL for 2 weekly measurements or when the patient is tolerating enough enteral nutrition so that PN is no longer needed. Clinical and laboratory monitoring will be continued for 2 weeks post Omegaven™ infusion and as indicated by events thereafter. Additional endpoint criteria are: patients receiving transplants; AST/ALT, GGTP, C-reactive protein and albumin, mortality, infection rates and types, and frequency of red blood cell transfusions; if infant worsens with treatment or does not tolerate treatment with Omegaven, specifically for the adverse event of severe uncontrolled bleeding as listed in the risk section.
Study Type
Expanded Access Type
- Individual Patients
- Treatment IND/Protocol
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
- SSM Health Cardinal Glennon Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age < 1 years; inpatient use only
- PN dependency (unable to meet nutritional needs solely by enteral nutrition);
- Present PNALD, as evidenced by two consecutive direct bilirubin > 3.0 mg/dL (at interval of one week);
Failed standard therapies to prevent the progression of liver disease:
Avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding and the use of Ursodiol, if possible.
- At the time the diagnosis PNALD is made, the patient is expected to continue PN at least an additional 3 weeks
Exclusion Criteria:
- Any other cause of chronic liver disease (i.e., hepatitis B or C, cystic fibrosis, biliary atresia, or alpha 1 anti-trypsin deficiency etc.)
- enrollment in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team);
- Lack of informed consent;
- Intent to transfer to another healthcare facility
- allergy to any seafood product, egg protein, and/or previous allergy to Omegaven
- active coagulopathy characterized by ongoing bleeding or by a requirement for clotting factor replacement (e.g. fresh frozen plasma or cryoprecipitate) to maintain homeostasis
- impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis
- unstable DM or hyperglycemia
- stroke/embolism
- collapse and shock
- undefined coma status
- recent MI
- cholestasis due to any reason other than PNALD
- active new infection at time of initiation of Omegaven
- hemodynamic instability
- unable to tolerate necessary laboratory monitoring
- severe renal insufficiency
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Diamond IR, Sterescu A, Pencharz PB, Wales PW. The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease. Pediatr Surg Int. 2008 Jul;24(7):773-8. doi: 10.1007/s00383-008-2174-0. Epub 2008 May 27.
- Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201. doi: 10.1542/peds.2005-2662.
- Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86. doi: 10.1542/peds.2007-2248.
- Alwayn IP, Gura K, Nose V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. doi: 10.1203/01.PDR.0000153672.43030.75. Epub 2005 Jan 19.
- Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W, Duggan C, Puder M, Lenders C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct;24(5):839-47. doi: 10.1016/j.clnu.2005.05.020.
- Steinbach M, Clark RH, Kelleher AS, Flores C, White R, Chace DH, Spitzer AR; Pediatrix Amino-Acid Study Group. Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant. J Perinatol. 2008 Feb;28(2):129-35. doi: 10.1038/sj.jp.7211889. Epub 2007 Dec 6.
- de Meijer VE, Gura KM, Le HD, Meisel JA, Puder M. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):541-7. doi: 10.1177/0148607109332773. Epub 2009 Jul 1.
- Park HW, Lee NM, Kim JH, Kim KS, Kim SN. Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis. J Nutr. 2015 Feb;145(2):277-83. doi: 10.3945/jn.114.204974. Epub 2014 Dec 17.
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16150
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Johannes Gutenberg University MainzUniversity of JenaCompletedNon-alcoholic Fatty Liver Disease | Fatty Liver, NonalcoholicGermany
-
The Cleveland ClinicCompleted
-
Hadassah Medical OrganizationUnknown
Clinical Trials on Omegaven
-
Children's & Women's Health Centre of British ColumbiaChild and Family Research InstituteUnknownCholestasis | Parenteral Nutrition Associated Liver Disease (PNALD)Canada
-
National Taiwan University HospitalUnknownCritical Ill Patients in SICUTaiwan
-
Midwestern Regional Medical CenterTerminatedCancer | Hepatic InjuryUnited States
-
Jagiellonian UniversityCompletedGastrointestinal SurgeryPoland
-
Li Shin HospitalCompleted
-
Mark PuderCompletedGastrointestinal Disease | Short Bowel Syndrome | Parenteral Nutrition Associated Liver DiseaseUnited States
-
General University Hospital, PragueCharles University, Czech Republic; Ministry of Health, Czech RepublicCompletedParenteral NutritionCzechia
-
DHR Health Institute for Research and DevelopmentApproved for marketingParenteral Nutrition Associated Liver Disease
-
Rush University Medical CenterApproved for marketingCholestasis | Total Parenteral Nutrition-induced CholestasisUnited States